Microdialysis evaluation of atomoxetine brain penetration and central nervous system pharmacokinetics in rats

Drug Metabolism and Disposition

Volumn 37, Issue 1, 2009, Pages 137-142

  Kielbasa, William ^a   Kalvass, J Cory ^a   Stratford, Robert ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG DISPOSITION; DRUG MECHANISM; DRUG PENETRATION; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG TRANSPORT; LOADING DRUG DOSE; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; MALE; MICRODIALYSIS; PROPYLAMINES; RATS; RATS, WISTAR; SPINAL CORD;

RATTUS;

EID: 58149467009     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.023119     Document Type: Article

References (17)

1. Biederman J (2005) Atteution-defidt/hyperactivity disorder: a selective overview. Biol Psychiatry 57:1215-1220.
2. Biederman J and Faraone SV (2002) Current concepts on the neurobiology of attention-deficit/hyperactivity disorder. J Atten Disord 6 (Suppl 1):S7-S16.
3. Bymaster FP, Katner JS, Nelson DL, Herarick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, and Perry KW (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699-711.
4. de Lange EC and Danhof M (2002) Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin Pharmacokinet 41:691-703.
5. Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, Chen C, Chen X, Choo E, Cianfrogna J, et al. (2005) The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 33:165-174.
6. Fridén M, Gupta A, Antonsson M, Bredberg U, and Hammarlund-Udenaes M (2007) In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids. Drug Metab Dispos 35:1711-1719.
7. Kalvass JC and Maurer TS (2002) Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 23:327-338.
8. Kalvass JC, Maurer TS, and Pollack GM (2007) Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios. Drug Metab Dispos 35:660-666.
9. Mahar Doan KM and Boje KM (2000) Theoretical pharmacokinetic and pharmacodynamic simulations of drug delivery mediated by blood-brain barrier transporters. Biopharm Drug Dispos 21:261-278.
10. Mattiuz EL, Ponsler GD, Barbuch RJ, Wood PG, Mullen JH, Shugert RL, Li Q, Wheeler WJ, Kuo F, Conrad PC, et al. (2003) Disposition and metabolic fate of atomoxetine hydrochloride: pharmacokinetics, metabolism, and excretion in the Fischer 344 rat and beagle dog. Drug Metab Dispos 31:88-97.
11. Maurer TS, Debartolo DB, Tess DA, and Scott DO (2005) Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos 33:175-181.
12. Rosenberg GA, Kyner WT, and Estrada E (1980) Bulk flow of brain interstitial fluid under normal and hyperosmolar conditions. Am J Physiol 238:F42-F49.
13. Sauer JM, Ring BJ, and Witcher JW (2005) Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet 44:571-590.
14. Seism JL, Powers KM, Artru AA, Lewis L, and Shen DD (2000) Probenecid-inhibitable efflux transport of valproic acid in the brain parenchymal cells of rabbits: a microdialysis study. Brain Res 884:77-86.
15. Shen DD, Artru AA, and Adkison KK (2004) Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv Drug Deliv Rev 56:1825-1857.
16. Summerfield SG, Read K, Begley DJ, Obradovic T, Hidalgo IJ, Coggon S, Lewis AV, Porter RA, and Jeffrey P (2007) Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction. J Pharmacol Exp Ther 322:205-213.
17. Szentistványi I, Patlak CS, Ellis RA, and Cserr HF (1984) Drainage of interstitial fluid from different regions of rat brain. Am J Physiol Renal Physiol 246:F835-F844.